

Laboratory Service Report

1-800-533-1710

Patient Name TEST,IMPLEMENTATION TESTING	Patient ID 321	Age 56	Gender M	Order # X100029007
Ordering Phys TESTING			•	DOB 05/23/1955
Client Order # X100029007	Account Information	1		Report Notes
Collected 04/20/2012 16:10	C7028846-DLMP RO 3050 SUPERIOR DR	IVE		
Printed 04/24/2012 10:48	ROCHESTER,MN 55	901		

Test	Flag	Results	Unit	Reference Value	Perform Site*
Lyme Disease Ab (IgG, IgM) Panel Lyme Disease Ab (IgG), IFA		<1:80	REPORTED 04/2	23/2012 12:35	Y03
Lyme Disease Ab (IgM), IFA		<1:10			8 Y03 8
Interpretation					Y03 8

ANTIBODY NOT DETECTED
REFERENCE RANGES: IgG <1:80
IgM <1:10

Borrelia burgdorferi is the causative agent of Lyme Disease. Specific antibody titers are measured using an indirect immunofluorescence assay (IFA). IgM-specific titers usually peak 4 to 6 weeks after onset of infection and may persist in the presence of disease. IgG levels begin to rise above background levels about 2 to 3 weeks after infection, and may stay elevated in cases of prolonged disease. Seronegative cases of Lyme Disease have been reported and alternate laboratory tests may be necessary to make a diagnosis (e.g., culture, PCR). Crossreactivity is shown with other Borrelia and Treponema species.

As recommended by the Food and Drug Administration (FDA Public Health Advisory, July 7, 1997), all samples with positive or equivocal results in the Lyme Disease C6 Antibody EIA (Screening) should be tested by Western Blot/Immunoblot. Positive or equivocal screening test results should not be interpreted as truly positive until verified as such using a confirmatory assay [e.g., Lyme Disease Antibodies (IgG, IgM), IBL (serum)]. The screening test and/or immunoblot for Lyme Disease antibodies may be falsely negative in early stages of Lyme Disease, including the period when erythema migrans is apparent.

This assay was developed and its performance characteristics have been determined by Focus Diagnostics. It has not been cleared or approved

Performing Site Legend on Last Page of Report

Patient Name	Collection Date and Time	Report Status
TEST, IMPLEMENTATION TESTING	04/20/2012 16:10	Final
Page 1 of 2		>> Continued on Next Page >>

^{*} Report times for Mayo performed tests are CST/CDT



Laboratory Service Report

1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
TEST, IMPLEMENTATION TESTING	321	56	M	X100029007
Ordering Phys				DOB
TESTING				05/23/1955
Client Order #	Account Informatio	n		Report Notes
X100029007				-
Collected	C7028846-DLMP RC	C7028846-DLMP ROCHESTER		
04/20/2012 16:10	3050 SUPERIOR DR	RIVE		
Printed	ROCHESTER,MN 55	5901		
04/24/2012 10:48				

Test Flag Results Unit Value Site*

by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

* Performing Site:

	3		
Y038	Focus Diagnostics, Inc.	Lab Director:	
1030	5785 Corporate Avenue Cypress, CA 90630-4750	Lab Director:	

Patient Name		Report Status	
TEST,IMPLEMENTATION TESTING	04/20/2012 16:10	Final	
Page 2 of 2		** End of Report **	

^{*} Report times for Mayo performed tests are CST/CDT